These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12954584)

  • 1. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.
    Chanan-Khan A; Szebeni J; Savay S; Liebes L; Rafique NM; Alving CR; Muggia FM
    Ann Oncol; 2003 Sep; 14(9):1430-7. PubMed ID: 12954584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
    Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
    J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies.
    Szebeni J; Baranyi L; Savay S; Milosevits J; Bunger R; Laverman P; Metselaar JM; Storm G; Chanan-Khan A; Liebes L; Muggia FM; Cohen R; Barenholz Y; Alving CR
    J Liposome Res; 2002; 12(1-2):165-72. PubMed ID: 12604051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model.
    Szebeni J; Bedőcs P; Urbanics R; Bünger R; Rosivall L; Tóth M; Barenholz Y
    J Control Release; 2012 Jun; 160(2):382-7. PubMed ID: 22421426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
    Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
    Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
    Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
    Picard M; Castells MC
    Clin Rev Allergy Immunol; 2015 Oct; 49(2):177-91. PubMed ID: 24740483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil).
    Skubitz KM; Skubitz AP
    Anticancer Drugs; 1998 Jan; 9(1):45-50. PubMed ID: 9491791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal doxorubicin: the good, the bad and the not-so-ugly.
    Szebeni J; Fülöp T; Dézsi L; Metselaar B; Storm G
    J Drug Target; 2016 Nov; 24(9):765-767. PubMed ID: 27030293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
    Szebeni J
    Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
    Szebeni J
    Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients.
    Ingen-Housz-Oro S; Pham-Ledard A; Brice P; Lebrun-Vignes B; Zehou O; Reitter D; Ram-Wolff C; Dupin N; Bagot M; Chosidow O; Beylot-Barry M
    Eur J Dermatol; 2017 Jun; 27(3):271-274. PubMed ID: 28524061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.
    Gabizon AA; Lyass O; Berry GJ; Wildgust M
    Cancer Invest; 2004; 22(5):663-9. PubMed ID: 15581046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures.
    Chan A; Shih V; Tham Chee Kian
    J Oncol Pharm Pract; 2007 Jun; 13(2):105-7. PubMed ID: 17873110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome.
    Wibroe PP; Ahmadvand D; Oghabian MA; Yaghmur A; Moghimi SM
    J Control Release; 2016 Jan; 221():1-8. PubMed ID: 26608877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
    Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
    Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.